Literature DB >> 7510292

Combinations of interferon with platinum complexes: synergistic and antagonistic effects on growth inhibition of MCF-7 and MDA-MB231 breast cancer cells.

A M Otto1.   

Abstract

The growth-inhibitory effects of combining interferons (IFN) with platinum(II) complexes were tested with the aim of comparing these in cultures of estrogen-receptor(ER)-negative MDA-MB231 and ER-positive MCF-7 breast cancer cell lines. Another aim was to test whether IFN as a biological response modifier could enhance the effect of the Pt complexes in vitro in an attempt to find an explanation for their more potent antitumor effects in in vivo models. Here it is shown that in both cell lines the combinations of different IFN with all three Pt complexes generally resulted in additive growth inhibition, as calculated by the product of the fraction of surviving cells obtained with each compound alone. Moreover, in MCF-7 cells natural IFN beta (nIFN beta) combined with aqua[meso-1,2-bis-(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] sulfatoplatinum(II) (meso-6-Pt) resulted in synergistic inhibition. This synergy could be attributed to the estrogenic property of meso-6-Pt, since the ligand and estradiol also enhanced the inhibitory effect of nIFN beta. In contrast, the combination of recombinant IFN gamma and meso-6-Pt was antagonistic in MDA-MB231 cells. These results show that, in spite of the similar responses of the ER-negative and ER-positive cells to each compound alone, these cells show unexpected differences in their sensitivity to combinations of IFN and the new Pt complex meso-6-Pt.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7510292     DOI: 10.1007/bf01236385

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  19 in total

1.  Dissociation of estrogenic and cytotoxic properties of an estrogen receptor-binding platinum complex in human breast cancer cell lines.

Authors:  A M Otto; M Faderl; H Schönenberger
Journal:  Cancer Res       Date:  1991-06-15       Impact factor: 12.701

2.  Ring-substituted [1,2-bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum (II) complexes: compounds with a selective effect on the hormone-dependent mammary carcinoma.

Authors:  J Karl; R Gust; T Spruss; M R Schneider; H Schönenberger; J Engel; K H Wrobel; F Lux; S T Haeberlin
Journal:  J Med Chem       Date:  1988-01       Impact factor: 7.446

3.  Recombinant human interferons alpha, beta and gamma reduce the antiproliferative action of cytarabine in K562 human myeloid leukaemia clonogenic cells.

Authors:  H R Maurer; H T Hassan; C Tsiriyotis; D A Spandidos
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

4.  Effect of natural beta-interferon on cell proliferation and steroid receptor level in human breast cancer cells.

Authors:  G Sica; V Natoli; C Stella; S Del Bianco
Journal:  Cancer       Date:  1987-11-15       Impact factor: 6.860

5.  Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin.

Authors:  C M Sorenson; M A Barry; A Eastman
Journal:  J Natl Cancer Inst       Date:  1990-05-02       Impact factor: 13.506

Review 6.  Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review.

Authors:  S Wadler; E L Schwartz
Journal:  Cancer Res       Date:  1990-06-15       Impact factor: 12.701

7.  Interferon-gamma and cytotoxic agents studied in combination using a soft agarose human tumor clonogenic assay.

Authors:  T Saito; M E Berens; C E Welander
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

8.  A phase II study of cis-diamminedichloroplatinum II for advanced breast cancer. Two dose schedules.

Authors:  S Martino; B A Samal; A Singhakowinta; S Yoshida; M Mackenzie; J Jain; V K Vaitkevicius
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

9.  Synergistic combination of menogarol and melphalan and other two drug combinations.

Authors:  B K Bhuyan; E G Adams; M Johnson; S L Crampton
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

10.  Effects of human recombinant alpha 2 arg-interferon and gamma-interferon on human breast cancer cell lines: dissociation of antiproliferative activity and induction of HLA-DR antigen expression.

Authors:  G Gastl; C Marth; E Leiter; C Gattringer; I Mayer; G Daxenbichler; R Flener; C Huber
Journal:  Cancer Res       Date:  1985-07       Impact factor: 12.701

View more
  2 in total

1.  Antiproliferative effects of interferon gamma in combination with alpha-difluoromethylornithine on human carcinoma cell cultures.

Authors:  M Klouche; H Kirchner; F Hölzel
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

2.  Synergistic interactions between interferon beta and carboplatin on SK-MEL 28 human melanoma cell growth inhibition in vitro.

Authors:  B Hübner; K Eckert; C Garbe; H R Maurer
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.